STOCK TITAN

MedWellAI flags going-concern doubt as revenue falls

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

MedWellAI, Inc. reported revenue of $76,390 for the three months ended September 30, 2026, versus $117,387 a year earlier; commissions were $76,390 and rental income was zero after its sole lease customer said on June 1, 2026, that it would not renew. Net loss attributable to shareholders narrowed to $287,173 from $651,878, while operating cash used fell to $101,182 from $170,781. Cash was $180,040 against current liabilities of $8,331,076.

As of September 30, 2026, current liabilities exceeded current assets by $8,133,007 and accumulated deficit was $90,550,518; MedWellAI said these conditions raise substantial doubt about its ability to continue as a going concern. A $500,000 promissory note was in default, with arrears of $611,799 as of November 16, 2026. A July 21, 2026, $225,000 convertible note produced $195,000 in net proceeds and calls for a $126,000 payment on December 29, 2026, followed by $21,000 monthly payments. Management concluded internal control over financial reporting was ineffective and identified three material weaknesses.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

3 major · 4 points

How the balance works

Positive

  • Moderate pointShareholder-attributable loss narrowed to $287,173 from $651,878.
  • Moderate pointOperating cash use fell to $101,182 from $170,781.

Negative

  • Major pointWorking-capital deficit reached $8,133,007; management cited substantial doubt about going concern.
  • Major pointThree material weaknesses left internal control over financial reporting ineffective.
  • Major pointDefaulted note arrearage totaled $611,799 as of November 16, 2026. 60% of market cap
  • Moderate pointQuarterly revenue fell to $76,390 from $117,387.

Filing Explained

As of September 30, 2026, 33,312,500 potentially dilutive preferred-conversion shares were excluded from diluted earnings per share, not reported as issued common shares.

MedWellAI reports that 6,500 Series C preferred shares were outstanding as of September 30, 2026, and that the July 21 note permits conversion into common shares only after an event of default; no common shares were issued during the quarter. Series C can be converted at the holder’s option using a conversion price based on the prior trading day’s closing price, while the note’s conversion price is 80% of the lowest trading price in the 10 trading days before conversion. If these instruments convert into common shares, the added shares would increase the share count and reduce existing holders’ percentage ownership.

As of September 30, 2026, the filing lists 33,312,500 potentially dilutive shares from convertible preferred stock as excluded from diluted earnings per share because they were anti-dilutive; this is a potential-share count, not issued common stock. The company also reports that 125,000 vested common shares for services and compensation had not been issued as of September 30, 2026; it reported 6,536,580 common shares outstanding on November 13, 2026.

Revenue $76,390 Three months ended September 30, 2026; $117,387 in 2025
Net loss attributable to shareholders $287,173 loss Three months ended September 30, 2026; $651,878 loss in 2025
Cash used in operating activities $101,182 Three months ended September 30, 2026; $170,781 in 2025
Cash $180,040 As of September 30, 2026
Current liabilities $8,331,076 As of September 30, 2026
Excess of current liabilities over current assets $8,133,007 As of September 30, 2026
Promissory note arrearage $611,799 As of November 16, 2026; the $500,000 note was in default
Convertible note principal $225,000 Note dated July 21, 2026
going concern financial
"substantial doubt about the Company's ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
material weakness financial
"these circumstances constitute a material weakness"
A material weakness is a significant flaw in the systems and checks a company uses to ensure its financial reports are accurate, meaning errors or fraud could happen and not be caught. For investors it matters because it raises the risk that reported results are unreliable—similar to finding a hole in a ship’s hull—potentially leading to corrected financials, regulatory action, reduced trust, and negative effects on stock value and borrowing costs.
original issue discount financial
"$25,000 original issue discount"
Original issue discount (OID) is the difference between a debt security’s face value and the lower price at which it is first sold, treated as additional interest that accrues over the life of the instrument. For investors it matters because OID raises the effective yield and changes taxable income and the holding’s cost basis over time — think of buying a $100 voucher for $90 and recognizing the $10 gain as earned interest as the voucher approaches maturity.
anti-dilutive financial
"all securities had an anti-dilutive effect"
A claim, security feature, or action described as anti-dilutive prevents or does not cause a reduction in existing shareholders’ per-share values when additional shares could be issued. For example, certain convertible securities or corporate actions are treated as anti-dilutive for earnings-per-share calculations if including them would raise EPS rather than lower it; investors watch this because it affects reported per-share metrics, ownership percentages, and valuation comparisons, like keeping pie slices the same size instead of making them smaller.
beneficial ownership limitations regulatory
"subject to certain beneficial ownership limitations"
Beneficial ownership limitations are rules or contractual caps that restrict how much of a company’s stock an individual or entity can be treated as owning or controlling for legal, regulatory or corporate-governance purposes. They matter to investors because such limits affect voting power, reporting obligations, takeover risk and the ability to increase a stake — like an elevator weight limit or a lane divider that prevents any one car from taking over the whole road.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were MedWellAI (MWAI)’s revenue and net loss for the quarter?

For the three months ended September 30, 2026, revenue was $76,390 and net loss attributable to shareholders was $287,173. In the year-earlier quarter, revenue was $117,387 and shareholder-attributable net loss was $651,878.

Why did MedWellAI (MWAI) cite substantial doubt about its ability to continue as a going concern?

As of September 30, 2026, current liabilities exceeded current assets by $8,133,007, and the company had an accumulated deficit of $90,550,518. Management said its plans include raising capital through debt and/or equity markets until operating funds can cover working capital requirements.

How can the holder convert MedWellAI’s (MWAI) July 2026 convertible note?

After an event of default, the holder may convert the note into common shares at 80% of the lowest trading price in the 10 trading days before conversion.

What material weaknesses did MedWellAI (MWAI) report?

The company cited a board without independent members or an audit committee financial expert, reliance on management review controls and an outside consultant because of segregation-of-duties constraints, and no written policy for approving, identifying and authorizing related-party transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2026

☐

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

 

Commission file number: 000-55681

 

MEDWELLAI, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Nevada

 

82-1725385

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification No.)

 

2380 Drew Street, Suite 3, Clearwater, Florida 33765

(Address of principal executive offices) (Zip Code)

 

(813) 384-8480

(Registrant’s Telephone Number, Including Area Code)

 

Securities registered under Section 12(b) of the Exchange Act: None.

 

Securities registered under Section 12(g) of the Exchange Act: Common Stock, $0.001 par value per share

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

N/A

 

N/A

 

N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒    No ☐.

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒    No ☐.

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated Filer

☒

Smaller reporting company

☒

Emerging growth company

☐

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐    No ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐    No ☒.

 

As of November 13, 2026, the registrant had 6,536,580 shares of its common stock, $0.001 par value, issued and outstanding.

 

 

 

 

TABLE OF CONTENTS

 

Page

 

PART I: FINANCIAL INFORMATION

 

 

Item 1.

Financial Statements

F-1

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

3

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

 

10

 

Item 4.

Controls and Procedures

 

10

 

 

 

 

PART II: OTHER INFORMATION

 

 

 

Item 1.

Legal Proceedings

 

12

 

Item 1A.

Risk Factors

 

12

 

Item 2.

Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities

 

12

 

Item 3.

Defaults upon Senior Securities

 

12

 

Item 4.

Mine Safety Disclosures

 

12

 

Item 5.

Other Information

 

12

 

Item 6.

Exhibits

 

13

 

 

 

 

SIGNATURES

 

14

 

 

 

2

Table of Contents

  

PART I – FINANCIAL INFORMATION

INDEX TO FINANCIAL STATEMENTS

 

 

 

Page

 

 

 

 

 

Condensed Consolidated Balance Sheets as of September 30, 2026 (unaudited) and June 30, 2026

 

F-2

 

 

 

 

 

Condensed Consolidated Statements of Operations for the Three Months Ended September 30, 2026 and 2025 (unaudited)

 

F-3

 

 

 

 

 

Condensed Consolidated Statement of Stockholders’ Equity (Deficit) for the Three Months Ended September 30, 2026 and 2025 (unaudited)

 

F-4

 

 

 

 

 

Condensed Consolidated Statements of Cash Flows for Three Months Ended September 30, 2026 and 2025 (unaudited)

 

F-5

 

 

 

 

 

Notes to Condensed Consolidated Financial Statements as of September 30, 2026 (unaudited)

 

F-6

 

 

 
F-1

Table of Contents

 

MedWellAI, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

 

September 30,

 

 

June 30,

 

 

 

 2026

 

 

 2026

 

 

 

 (Unaudited)

 

 

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash

 

$180,040

 

 

$86,222

 

Receivables

 

 

3,029

 

 

 

9,099

 

Prepaid expenses and other current assets

 

 

9,000

 

 

 

10,556

 

Deposits, Current

 

 

6,000

 

 

 

6,000

 

Total current assets

 

 

198,069

 

 

 

111,877

 

 

 

 

 

 

 

 

 

 

Other assets:

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

703

 

 

 

890

 

Intangible assets, net

 

 

21,742

 

 

 

27,680

 

Total other assets

 

 

22,445

 

 

 

28,570

 

 

 

 

 

 

 

 

 

 

TOTAL ASSETS

 

$220,514

 

 

$140,447

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$143,093

 

 

$137,904

 

Accrued expenses

 

 

145,106

 

 

 

110,121

 

Due to related party

 

 

842,041

 

 

 

711,115

 

Notes payable in default, net of debt discount

 

 

500,000

 

 

 

500,000

 

Convertible notes payable, net of debt discount

 

 

200,836

 

 

 

-

 

Series C convertible preferred stock, $0.001 par value, 6,500 shares authorized, 6,500 shares issued and outstanding as of September 30, 2026 and June 30, 2026

 

 

6,500,000

 

 

 

6,500,000

 

Total current liabilities

 

 

8,331,076

 

 

 

7,959,140

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Stockholders' equity (deficit):

 

 

 

 

 

 

 

 

Series A preferred stock, $0.001 par value, 1,000,000 shares authorized, 500,000 shares issued and outstanding as of September 30, 2026 and June 30, 2026

 

 

500

 

 

 

500

 

Series B preferred stock, $0.001 par value, 1,500,000 shares authorized, 130,000 shares issued and outstanding as of September 30, 2026 and June 30, 2026

 

 

130

 

 

 

130

 

Common stock payable

 

 

124,750

 

 

 

83,708

 

Common stock, $0.001 par value, 300,000,000 shares authorized, 6,536,580 issued and outstanding as of September 30, 2026 and June 30, 2026

 

 

6,537

 

 

 

6,533

 

Additional paid in capital

 

 

82,152,017

 

 

 

82,193,063

 

Accumulated deficit

 

 

(90,550,518 )

 

 

(90,263,345 )

Total Stockholders' deficit of MedWellAI, Inc. and Subsidiaries

 

 

(8,266,584 )

 

 

(7,979,411 )

Noncontrolling interest

 

 

156,022

 

 

 

160,718

 

Total stockholders' deficit

 

 

(8,110,562 )

 

 

(7,818,693 )

 

 

 

 

 

 

 

 

 

Total liabilities and stockholders' deficit

 

$220,514

 

 

$140,447

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

  

 
F-2

Table of Contents

 

MedWellAI, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

 

 

Three Months Ended September 30,

 

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

Revenue:

 

 

 

 

 

 

Commissions

 

$76,390

 

 

$94,887

 

Rental income

 

 

 -

 

 

 

22,500

 

Total revenue

 

 

76,390

 

 

 

117,387

 

 

 

 

 

 

 

 

 

 

Costs and expenses:

 

 

 

 

 

 

 

 

Cost of revenues - rent

 

 

-

 

 

 

7,550

 

General and administrative

 

 

316,195

 

 

 

428,771

 

Depreciation and amortization

 

 

6,125

 

 

 

8,307

 

Total operating expenses

 

 

322,320

 

 

 

444,628

 

 

 

 

 

 

 

 

 

 

Income (loss) from operations

 

 

(245,930)

 

 

(327,241)

 

 

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

 

 

 

Other income

 

 

-

 

 

 

1,207

 

Interest expense

 

 

(45,939)

 

 

(12,936)

Loss on exchange of Series C & D preferred shares

 

 

-

 

 

 

(241,918)

Total other income (expense)

 

 

(45,939)

 

 

(253,647)

 

 

 

 

 

 

 

 

 

Income (loss) from continued operations before income taxes

 

 

(291,869)

 

 

(580,888)

Provision for income taxes

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Net income (loss) from continued operations

 

 

(291,869)

 

 

(580,888)

Net income (loss) from discontinued operations

 

 

-

 

 

 

(72,719)

 

 

 

 

 

 

 

 

 

Net income (loss)

 

 

(291,869)

 

 

(653,607)

Net income (loss) attributable to noncontrolling interest

 

 

(4,696)

 

 

(1,729)

Net income (loss) attributable to MedWellAI, Inc.

 

 

(287,173)

 

 

(651,878)

 

 

 

 

 

 

 

 

 

Dividends on Preferred Stock

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to shareholders

 

$(287,173)

 

$(651,878)

 

 

 

 

 

 

 

 

 

Continuing operations:

 

 

 

 

 

 

 

 

Net income (loss) per common share attributable to shareholders, basic

 

$(0.04)

 

$(0.09)

Net income (loss) per common share attributable to shareholders, diluted

 

$(0.04)

 

$(0.09)

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding, basic

 

 

6,536,580

 

 

 

6,186,580

 

Weighted average number of common shares outstanding, diluted

 

 

6,536,580

 

 

 

6,186,580

 

Discontinuing operations:

 

 

 

 

 

 

 

 

Net income (loss) per common share attributable to shareholders, basic

 

$-

 

 

$(0.01)

Net income (loss) per common share attributable to shareholders, diluted

 

$-

 

 

$(0.01)

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding, basic

 

 

6,536,580

 

 

 

6,186,580

 

Weighted average number of common shares outstanding, diluted

 

 

6,536,580

 

 

 

6,186,580

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 
F-3

Table of Contents

 

MedWellAI, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

THREE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Series C

 

 

Series D

 

 

Series A

 

 

Series B

 

 

 

 

 

Common

 

 

Additional

 

 

 

 

 

Non

 

 

 

 

 

 

Preferred Stock

 

 

Preferred Stock

 

 

Preferred Stock

 

 

Preferred Stock

 

 

Common Stock

 

 

Stock

 

 

Paid in

 

 

Accumulated

 

 

controlling

 

 

 

 

 

 Shares

 

 

 Amount

 

 

 Shares

 

 

 Amount

 

 

 Shares

 

 

 Amount

 

 

Shares

 

 

 Amount

 

 

 Shares

 

 

 Amount

 

 

 Payable

 

 

 Capital

 

 

 Deficit

 

 

 Interest

 

 

 Total

 

Balance, June 30, 2025

 

 

1,125

 

 

$1,125,000

 

 

 

3,000

 

 

$3,000,000

 

 

 

500,000

 

 

$500

 

 

 

130,000

 

 

$130

 

 

 

6,186,580

 

 

$6,183

 

 

$26,250

 

 

$82,016,218

 

 

$(88,673,880 )

 

$164,164

 

 

$(6,460,435 )

Share exchange agreement with BHP Capital

 

 

(1,125 )

 

 

(1,125,000 )

 

 

(3,000 )

 

 

(3,000,000 )

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Common stock issued for services

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

50,000

 

 

 

50

 

 

 

-

 

 

 

49,200

 

 

 

-

 

 

 

-

 

 

 

49,250

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(651,878 )

 

 

(1,729 )

 

 

(653,607 )

Balance, September 30, 2025

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

500,000

 

 

$500

 

 

 

130,000

 

 

$130

 

 

 

6,236,580

 

 

$6,233

 

 

$26,250

 

 

$82,065,418

 

 

$(89,325,758 )

 

$162,435

 

 

$(7,064,792 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, June 30, 2026

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

500,000

 

 

$500

 

 

 

130,000

 

 

$130

 

 

 

6,536,580

 

 

$6,533

 

 

$83,708

 

 

$82,193,063

 

 

$(90,263,345 )

 

$160,718

 

 

$(7,818,693 )

Rounding adjustment

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

4

 

 

 

-

 

 

 

(4)

 

 

-

 

 

 

-

 

 

 

-

 

Common stock payable for shares vested but not issued

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

41,042

 

 

 

(41,042)

 

 

-

 

 

 

-

 

 

 

-

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(287,173 )

 

 

(4,696 )

 

 

(291,869 )

Balance, September 30, 2026

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

500,000

 

 

$500

 

 

 

130,000

 

 

$130

 

 

 

6,536,580

 

 

$6,537

 

 

$124,750

 

 

$82,152,017

 

 

$(90,550,518 )

 

$156,022

 

 

$(8,110,562 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 
F-4

Table of Contents

 

MedWellAI, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

 

Three Months Ended September 30,

 

 

 

2026

 

 

2025

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net income (loss) from continuing operations

 

$(291,869)

 

$(580,888)

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

6,125

 

 

 

8,307

 

Debt discount amortization

 

 

5,836

 

 

 

-

 

Stock-based compensation

 

 

-

 

 

 

49,250

 

Loss on exchange of Series C & D preferred stock

 

 

-

 

 

 

241,918

 

Lease cost, net of repayment

 

 

-

 

 

 

7,550

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Receivables

 

 

6,070

 

 

 

287

 

Prepaid expenses and other current assets

 

 

1,556

 

 

 

(1,244)

Accounts payable

 

 

5,189

 

 

 

(27,655)

Accrued expenses

 

 

34,985

 

 

 

13,309

 

Deferred revenue

 

 

-

 

 

 

(203)

Due to related party

 

 

130,926

 

 

 

118,588

 

Net cash provided by (used in) operating activities

 

 

(101,182)

 

 

(170,781)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Purchase of leasehold improvements

 

 

-

 

 

 

(7,308)

Net cash provided by (used in) investing activities

 

 

-

 

 

 

(7,308)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Cash proceeds from convertible note payable

 

 

195,000

 

 

 

-

 

Net cash provided by (used in) financing activities

 

 

195,000

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Net increase (decrease) in cash

 

 

93,818

 

 

 

(178,089)

Cash, cash equivalents, and restricted cash - beginning of period

 

 

86,222

 

 

 

401,310

 

Cash, cash equivalents, and restricted cash - end of period

 

$180,040

 

 

$223,221

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

 

 

 

 

 

 

 

 

Cash paid during the period for:

 

 

 

 

 

 

 

 

Interest

 

$-

 

 

$-

 

Income taxes

 

$-

 

 

$-

 

Non-cash investing and financing activities - continuing:

 

 

 

 

 

 

 

 

Debt discount

 

$5,000

 

 

$-

 

Original issue discount

 

$25,000

 

 

$-

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

 
F-5

Table of Contents

 

MedWellAI, Inc.

Notes to Condensed Consolidated Financial Statements

Three Months Ended September 30, 2026

(Unaudited)

 

1. ORGANIZATION AND BASIS OF PRESENTATION

 

Organization

 

We were incorporated in the State of Nevada on March 22, 2011 under the name Lightcollar, Inc. In March 2015, we changed our name to EMS Find, Inc. On May 30, 2017, Integrated Ventures, Inc. (“Integrated Ventures”), a Nevada corporation, was formed as a wholly owned subsidiary of the Company. Pursuant to an Agreement and Plan of Merger dated May 30, 2017, Integrated Ventures was merged into the Company, with the Company being the surviving corporation and changing its name to Integrated Ventures, Inc. In July 2024, the Company formed three wholly-owned subsidiaries, MedWell Direct, LLC (“MedWell Direct”), MedWell Facilities, LLC (“MedWell Facilities”), and MedWell USA, LLC (“MedWell USA”), all of which were organized in the State of Nevada. In June 2025, we changed our name to MedWellAI, Inc.

 

On August 29, 2024, the Company, through MedWell Direct, consummated its acquisition of 51% of the membership interests of Healthy Lifestyle USA LLC, a Florida limited liability company (“Healthy Lifestyle”).

 

We are a publicly traded company (OTCQB: MWAI), based in Clearwater, Florida, that is focused on earning commissions through the use of a fully automated e-commerce platform that connects in-office buyers with multiple FDA-registered 503B pharmacies, offering GLP-1 weight management therapies, peptides and other compounds.

 

The Company also markets a turnkey, custom solution for qualified procurement agents and resellers to market in-office use products.

 

This e-commerce platform enables procurement agents and resellers to market products to licensed healthcare providers, wellness spas and telemedicine companies in a 100% automated, cost-effective, efficient, compliant and profitable manner without requiring any infrastructure investment.

 

Key features of the platform include access to multiple 503B outsourcing facilities, over 100 products, personalized pricing, direct payment deposits, custom domain options, and onboarding support.

 

The platform allows for seamless ordering, fulfillment, and shipping managed directly by the 503B facilities.

 

Basis of Presentation

 

The accompanying unaudited financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles ("US GAAP") for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. The results of operations for the interim period ended September 30, 2026 shown in this report are not necessarily indicative of results to be expected for the full fiscal year ending June 30, 2027. In the opinion of the Company's management, the information contained herein reflects all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of the Company's results of operations, financial position and cash flows. The unaudited interim financial statements should be read in conjunction with the audited financial statements in the Company's Annual Report on Form 10-K for the year ended June 30, 2026 filed on October 13, 2026 and Management's Discussion and Analysis of Financial Condition and Results of Operations.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The significant accounting policies of the Company are disclosed in Notes to Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2026 filed on October 13, 2026. The following summary of significant accounting policies of the Company is presented to assist in understanding the Company’s interim financial statements. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.

 

 
F-6

Table of Contents

 

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.

 

Reclassification

 

Certain accounts from prior periods have been reclassified to conform to the current period presentation.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, MedWell Direct, MedWell Facilities, and Medwell USA. The Company owns 51% of Healthy Lifestyle, which has been included in the consolidated financial statements and the Company has recorded a noncontrolling interest for the 49% interest that they do not own.

  

All significant intercompany transactions and balances have been eliminated.

 

Cash and Cash Equivalents

 

The Company maintains cash balances in non-interest-bearing accounts that at times may exceed federally insured limits. For the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. The Company had no cash equivalents at September 30, 2026.

 

Receivables

 

Receivables are carried at net realizable value, representing the outstanding balance less an allowance for doubtful accounts based on a review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual receivables and receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded when received. We had an allowance for doubtful accounts of $0 and $0 as of September 30, 2026 and June 30, 2026, respectively.

 

Property and Equipment

 

Property and equipment, consisting primarily of computer, other equipment, and leasehold improvements is stated at the lower of cost or estimated realizable value and is depreciated when placed into service using the straight-line method over estimated useful lives. Management has assessed the basis of depreciation of these assets and believes they should be depreciated over three – five years depending on the asset. Computers, due to their technological obsolescence reflecting rapid development of hardware that have faster processing capacity and other factors are depreciated over three years. Leasehold improvements are depreciated over five years representing the lease term. Maintenance and repairs are expensed as incurred and improvements are capitalized. Gains or losses on the disposition of property and equipment are recorded upon disposal.

 

Intangible Assets

 

The Company accounts for its intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Subtopic 350-30, General Intangibles Other Than Goodwill. ASC Subtopic 350-30, which requires assets to be measured based on the fair value of the consideration given or the fair value of the assets (or net assets) acquired, whichever is more clearly evident and, thus, more reliably measurable. Under ASC Subtopic 350-30 any intangible asset with a useful life is required to be amortized over that life and the useful life is to be evaluated every reporting period to determine whether events or circumstances warrant a revision to the remaining period of amortization. If the estimate of useful life is changed the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. Costs to renew or extend the term of intangible assets are recognized as an expense when incurred.

 

 
F-7

Table of Contents

 

 

Impairment of Long-Lived Assets

 

All assets, including intangible assets subject to amortization, are reviewed for impairment when changes in circumstances indicate that the carrying amount of the asset may not be recoverable in accordance with ASC 350 and ASC 360. If the carrying amount of the asset exceeds the expected undiscounted cash flows of the asset, an impairment charge is recognized equal to the amount by which the carrying amount exceeds fair value or net realizable value. The testing of these intangibles under established guidelines for impairment requires significant use of judgment and assumptions. Changes in forecasted operations and other assumptions could materially affect the estimated fair values. Changes in business conditions could potentially require adjustments to these asset valuations.

 

Leases

 

The Company follows the provisions of ASC 842, and records right-of-use (“ROU”) assets and lease obligations for its operating leases, which are initially recognized based on the discounted future lease payments over the term of the lease. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. If the rate implicit in the Company's leases is not readily determinable, the Company's applicable incremental borrowing rate is used in calculating the present value of the sum of the lease payments.

 

The lease term is defined as the non-cancelable period of the lease plus any options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company has elected not to recognize ROU asset and lease obligations for its short-term leases, which are defined as leases with an initial term of 12 months or less.

 

Discontinued Operations

 

The Company follows the provisions of ASC 205-20, Presentation of Discontinued Operations, which requires separate reporting if a company sells part of its business. In order to recognize discontinued operation a major product line or division of an entity must be both a component and a strategic shift in operations. The Company assessed its digital asset mining business in June 2024 and determined it met the criteria of ASC 205-20. We disclosed our discontinued operations separately in the consolidated balance sheets, statements of operations, and statements of cash flows as items held for sale and discontinued operations. See Note 13.

 

Convertible Preferred Stock

 

The Company follows the provisions of ASC 480, Distinguishing Liabilities from Equity in determining if a financial instrument should be classified as a liability or equity on the balance sheet. This standard provides, among others, that the conversion of preferred stock into a variable number of equity shares and at inception, the monetary value is fixed, the instrument should be classified as a liability. As such upon the exchange of the Series C & D preferred shares on August 1, 2025 into convertible preferred stock, the Company determined the Series C convertible preferred stock met the requirements to be classified as a liability. Further, due to their convertible nature at any time at the option of the holder they are presented as current liability on the balance sheet.

 

Stock-Based Compensation

 

The Company accounts for all equity-based payments in accordance with ASC Topic 718, Compensation – Stock Compensation. ASC Topic 718 requires companies to recognize in the statement of operations the grant-date fair value of stock awards, stock options, warrants and other equity-based compensation issued to employees. The value of the portion of an award that is ultimately expected to vest is recognized as an expense over the requisite service periods using the straight-line attribution method. The fair value of a stock award is recorded at the fair market value of a share of the Company’s stock on the grant date. The Company estimates the fair value of stock options and warrants at the grant date by using an appropriate fair value model such as the Black-Scholes option pricing model or multinomial lattice models.

 

 
F-8

Table of Contents

 

 

Revenue Recognition

 

We recognize revenue in accordance with ASC 606, Revenue from Contracts with Customers. This standard provides a single comprehensive model to be used in the accounting for revenue arising from contracts with customers, including industry-specific guidance. The standard’s stated core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects in the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASC 606 includes provisions within a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.

 

The following table presents the Company’s revenue by revenue source:

 

 

 

Three Months Ended

September 30

 

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

Commissions

 

$76,390

 

 

$94,887

 

Rental income

 

 

-

 

 

 

22,500

 

 

 

$76,390

 

 

$117,387

 

 

Commissions

 

The Company earns commissions by informing, educating, and initiating sales of health and wellness products offered by a third party to customers. The commissions earned is based on the gross sales of products to customers less costs and fees. Through the use of their e-commerce platform, the third party computes the commission payable after each sale. The third party then pays the Company the amount due. The transactions price is set as the commissions to be received based on the agreed terms. The commissions are earned at a point in time upon the successful sale of products to a customer.

 

The timing of commission revenue recognition may differ from the timing of payment by the Company’s customers. The Company records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. As of September 30, 2026, the Company had receivables from commissions of $3,029.

 

Rental Income

 

The Company recognizes rent revenue from the lease of its sub-leased properties in accordance with ASC 842, Leases. The sub-lease is categorized as an operating lease according to ASC criteria for the lease definitions. Rent revenue is recognized on a straight-line basis over the lease term, reflecting the pattern of the economic benefits derived from the lease.

 

The Company’s leases generally have fixed rental payments over the lease term, with occasional escalations based on predetermined factors. Rent revenue is recognized monthly as the lessor fulfills its obligations under the lease agreement.

 

Any lease incentives or concessions provided to lessees, such as rent-free periods or tenant improvement allowances, are recognized as a reduction of rent revenue over the lease term.

 

During the year ended June 30, 2026, the Company had only one lease arrangement with a single customer. On June 1, 2026 the customer notified the Company the lease would not be renewed.

 

 
F-9

Table of Contents

 

 

Income Taxes

 

Income taxes are recorded in accordance with ASC Topic 740, Income Taxes, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.

 

Management judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities, and any valuation allowance recorded against our deferred tax assets. Deferred tax assets are reduced by a valuation allowance if, based on the consideration of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Changes in assumptions in future periods may require we adjust our valuation allowance, which could materially impact our financial position and results of operations. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return, if such a position is more likely than not to be sustained.

 

Net Income (Loss) Per Share

 

Basic net income or loss per share is calculated by dividing net income or loss by the weighted average number of common shares outstanding for the period. Diluted income or loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock, such as “in-the-money” stock options and warrants, convertible debt and convertible preferred stock, were exercised or converted into common stock. Equivalent shares are not utilized when the effect is anti-dilutive. For the three months ended September 30, 2026 and 2025 basic and diluted income per share were the same, as all securities had an anti-dilutive effect.

 

 
F-10

Table of Contents

 

 

The following table presents potentially dilutive securities that were not included in the computation of diluted net income per share as their inclusion would be anti-dilutive as of September 30:

 

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

Convertible preferred stock

 

 

33,312,500

 

 

 

25,777,669

 

 

Fair Value of Financial Instruments

 

Assets and liabilities measured at fair value on a recurring basis

 

We recognize financial instruments under the following fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows:

 

 

Level 1:

quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

 

 

 

Level 2:

observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

 

 

 

Level 3:

assets and liabilities whose significant value drivers are unobservable.

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

 

The Company will update its assumptions each reporting period based on new developments and record such amounts at fair value based on the revised assumptions until the agreements expire or contingency is resolved, as applicable.

 

As of September 30, 2026 and June 30, 2026 the Company did not have any assets and liabilities measured at fair value on a recurring basis.

 

Assets and liabilities not measured at fair value on a recurring basis

 

In addition to assets and liabilities that are measured at fair value on a recurring basis, we also measure certain assets and liabilities at fair value on a nonrecurring basis. Our non-financial assets, including goodwill, property and equipment, intangible assets, and operating lease right-of-use assets are measured at fair value when there is an indication of impairment and the carrying amount exceeds the asset’s projected undiscounted cash flows. These assets are recorded at fair value only when an impairment charge is recognized.

 

As of September 30, 2026 and June 30, 2026, the fair values of cash, receivables, prepaid expenses and other current assets, accounts payable, and accrued expenses approximated their carrying values because of their short-term nature.

 

Recently Issued Accounting Pronouncements

 

There were no new accounting pronouncements issued or proposed by the FASB during the three months ended September 30, 2026 and through the date of filing this report which the Company believes will have a material impact on its financial statements.

 

 
F-11

Table of Contents

 

3. GOING CONCERN

 

Historically, the Company has reported recurring net losses from operations and used net cash in operating activities. As of September 30, 2026, the Company’s current liabilities exceeded its current assets by $8,133,007 and the Company had an accumulated deficit of $90,550,518. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

 

The accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The ability of the Company to reach and maintain a successful level of operations is dependent on the execution of management’s plans, which include the raising of capital through the debt and/or equity markets, until such time that funds provided by operations are sufficient to fund working capital requirements. If the Company were not to continue as a going concern, it would likely not be able to realize its assets at values comparable to the carrying value or the fair value estimates reflected in the balances set out in the preparation of the financial statements.

 

There can be no assurances that the Company will be successful in attaining a profitable level of operations or in generating additional cash from the equity/debt markets or other sources fund its operations. The financial statements do not include any adjustments relating to the recoverability of assets and classification of assets and liabilities that might be necessary. Should the Company not be successful in its business plan or in obtaining the necessary financing to fund its operations, the Company would need to curtail certain or all operational activities and/or contemplate the sale of its assets, if necessary.

 

4. OPERATING SEGMENTS

 

Operating segments are defined as components of an entity for which separate financial information is available that is regularly reviewed by the chief operating decision maker (“CODM”). The CODM is the Chief Executive Officer. The CODM uses segment net income from operations to assess the performance of, manage the operations of, and allocate capital and operational resources to the Company’s reportable operating segments. The Company does not allocate assets to the reporting segments as its assets are primarily managed on an entity-wide basis and therefore does not disclose the total assets of its reportable operating segments.

 

Prior to June 11, 2025, the Company operated as a single operating segment, focusing on distributing pharmaceutical products, particularly GLP medications for weight loss and diabetes management.

 

Starting June 11, 2025, the Company has two reportable segments, focusing on distributing pharmaceutical products, particularly GLP medications for weight loss and diabetes management, and developing real estate opportunities, designed to attract healthcare providers and wellness clinic operators.

 

For the three months ended September 30, 2026 and 2025, there were no intersegment revenues or costs of revenues that needed to be eliminated in the Consolidated Statements of Operations.

 

The pharmaceutical products distribution company generates revenue through product sales and commissions. Real estate development company generates revenue through rental income. On June 1, 2026, the Company’s only rental customer informed the Company they would not be renewing their lease, thus there was no real estate segment operating activity in the three months ended September 30, 2026.

  

 
F-12

Table of Contents

 

 

The following table illustrates segment revenue and segment net income from operations, including significant expense items reviewed by the CODM for the three months ended September 30, 2026.

 

 

 

Pharmaceutical Products Distribution

 

 

Real Estate Development

 

 

Total

 

Revenue

 

$76,390

 

 

$-

 

 

$76,390

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Less:

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative[1]

 

 

316,195

 

 

 

-

 

 

 

316,195

 

Depreciation and amortization

 

 

6,125

 

 

 

-

 

 

 

6,125

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Segment net income (loss) from operations

 

$(245,930)

 

$-

 

 

$(245,930)

 

[1]

General and administrative costs consist mainly of professional fees, salaries and wages, executive compensation, information technology and software, and other payment processing fees.

 

The following table illustrates the reconciliation of segment operating income to net income before taxes for the three months ended September 30, 2026.

 

 

 

September 30,

2026

 

Segment loss from operations

 

$(245,930)

 

 

 

 

 

Reconciling items

 

 

 

 

Interest expense

 

 

(45,939)

 

 

 

 

 

Net income (loss) from continued operations before income taxes

 

$(291,869)

 

5. PROPERTY AND EQUIPMENT

 

Property and equipment consisted of the following as of:

 

 

 

September 30,

2026

 

 

June 30,

2026

 

 

 

 

 

 

 

 

Furniture and equipment

 

$2,242

 

 

$2,242

 

Leasehold improvements

 

 

-

 

 

 

9,978

 

 

 

 

 

 

 

 

 

 

Total

 

 

2,242

 

 

 

12,220

 

Less accumulated depreciation and amortization

 

 

(1,539)

 

 

(11,330 )

 

 

 

 

 

 

 

 

 

Net

 

$703

 

 

$890

 

 

During the three months ended September 30, 2026 the Company disposed of its fully depreciated leasehold improvements for no gain or loss. Depreciation expense for the three months ended September 30, 2026 and 2025 was $187 and $2,369, respectively.

 

 
F-13

Table of Contents

 

6. INTANGIBLE ASSETS

 

Intangible assets consisted of the following as of:

 

 

 

Useful Lives

 

September 30,

2026

 

 

June 30,

2026

 

 

 

 

 

 

 

 

 

 

Website

 

3 years

 

$71,250

 

 

$71,250

 

Less accumulated amortization

 

 

 

 

(49,508 )

 

 

(43,570 )

Net website

 

 

 

$21,742

 

 

$27,680

 

 

Amortization expense for the three months ended September 30, 2026 and 2025 was $5,938.

 

7. RELATED PARTY TRANSACTIONS

 

We have one executive officer, Steve Rubakh, who is currently the sole member of our Board of Directors. The Board of Directors establishes Mr. Rubakh’s annual salary, cash bonuses, and the number of Series B preferred stock to issue Mr. Rubakh as additional compensation. Effective January 1, 2024, the Board of Directors approved Mr. Rubakh’s annual salary at $250,000, quarterly cash bonus to be $100,000.

 

During the three months ended September 30, 2026 and 2025, Mr. Rubakh’s annual salary was $250,000 ($62,500 quarterly). In addition, $100,000 of bonuses were approved by the Board of Directors.

 

Total compensation expense included in general and administrative expenses was $162,500 each for the three months ended September 30, 2026 and 2025, respectively. Amounts due to related party, consisting of accrued salary to Mr. Rubakh, totaled $842,041, and $711,115 as of September 30, 2026 and June 30, 2026, respectively.

 

8. NOTES PAYABLE

 

On June 15, 2022, the Company entered into a Loan Agreement and Promissory Note with BHP Capital NY, Inc. (“BHP”) in the amount of $500,000. The note matured on January 15, 2023, and bears a flat interest charge of $130,000 that shall not be reduced or pro-rated in the event of prepayment. In addition, upon an event of default, the Note bears default interest of 18% per annum. Effective April 1, 2024, the lender agreed to reduce the default interest to 10% per annum. This note is secured by assets and equipment of the Company. As further inducement to enter this note, the Company issued BHP 16,000 shares or restricted common stock. These shares were valued at $123,200 using the closing market price of the Company’s common stock on the date of issuance and were recorded as a debt discount that was amortized to interest expense over the term of the note. The Company accrued $12,778 of interest expense on this note during each of the three months ended September 30, 2026 and 2025. Accrued interest was $111,799 and $99,021 as of September 30, 2026 and June 30, 2026, respectively. The outstanding principal balance of this note was $500,000 as of September 30, 2026 and June 30, 2026. This note is in default due to nonpayment before the maturity date.

 

9. CONVERTIBLE NOTES PAYABLE

 

On July 21, 2026, the Company entered into a convertible note payable for $225,000. The note matures on July 21, 2027 and bears a flat interest charge of $27,000 that shall not be reduced or pro-rated in the event of prepayment. In addition, upon an event of default the interest rate will be equal to the lesser of 24% or the maximum rate of interest under the law. The convertible note requires a payment of $126,000 on December 29, 2026 with payments of $21,000 each month thereafter until the maturity of the note. At anytime after an event of default, the holder may convert the note into common shares at a rate per share equal to 80% of the lowest trading price in the 10 trading days prior to conversion. The Company received net proceeds of $195,000 after recording a $25,000 original issue discount and $5,000 in debt discount for legal fees. The total debt discount of $30,000 will be amortized over the life of the loan. During the three months ended September 30, 2026 the Company recorded $27,000 of interest expense and amortized $5,836 of the debt discount to interest expense. Accrued interest was $27,000 as of September 30, 2026. As of September 30, 2026 the principal balance owed on the convertible note is $225,000, the debt discount balance is $24,164 and the carrying value is $200,836.

 

 
F-14

Table of Contents

 

10. SERIES C CONVERTIBLE PREFERRED STOCK

 

Effective August 1, 2025, the Company amended and restated the Certificate of Designation for its Series C Preferred Stock, effecting the consolidation of the Series C Preferred Stock and Series D Preferred Stock classes into a single series of convertible preferred stock. Per the share exchange agreement, 1,125 shares of Series C Preferred Stock and 3,000 shares of Series D Preferred Stock were exchanged for 6,500 Series C Convertible Preferred shares. Each share of Series C convertible preferred stock had a par value of $0.001 per share and a stated value of $1,000 per share. Concurrent to this agreement, $2,133,081 in accrued and unpaid dividends were retired and the Company recognized a loss on exchange of $0 and $241,918 for the three months ended September 30, 2026 and 2025, respectively.

 

Dividends. Holders of Series C Convertible Preferred Stock shall be entitled to receive, and the Company shall pay, dividends on shares of Series C Convertible Preferred Stock equal to (on an as-if-converted-to-Common-Stock basis) and in the same form as dividends actually paid on shares of the Company’s Common Stock (the “Common Stock”) when, as and if such dividends are paid on shares of the Common Stock.

 

Voting Rights. The Series C Convertible Preferred Stock will vote together with the Common Stock on an as-converted basis subject to certain beneficial ownership limitations. In addition, for as long as any shares of Series C Convertible Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series C Convertible Preferred Stock (a) amend or alter the rights, powers, or preferences of the Series C Convertible Preferred Stock; (b) authorize or issue any class of stock senior to, or otherwise pari passu with, the Series C Convertible Preferred Stock; (c) amend the Company’s charter documents in a way that adversely affects the Series C Convertible Preferred Stock; (d) increase the number of authorized shares of Series C Convertible Preferred Stock; or (e) enter into any agreement with respect to any of the foregoing.

 

Liquidation. Upon any Liquidation (as defined in the Certificate of Amendment), holders of Series C Convertible Preferred Stock shall be entitled to receive the Stated Value of their shares plus any accrued and unpaid dividends or other applicable fees, before any distribution is made to holders of junior securities. If the Company’s assets are insufficient to pay all such amounts in full, they will be distributed pro rata among holders of Series C Convertible Preferred Stock based on the amounts otherwise payable.

 

Conversion. Each share of Series C Convertible Preferred Stock shall be convertible, at any time and from time to time at the option of the holder thereof, into the number of shares of Common Stock, subject to certain ownership limitations set forth in the Certificate of Amendment. The number of shares of Common Stock issuable upon conversion by dividing the Stated Value of the Series C Convertible Preferred Stock by the Conversion Price, which equals to the previous Trading Day’s closing price of the Common Stock. The Conversion Price is subject to adjustments and restrictions set forth in Section 7 of the Certificate of Amendment.

 

As of September 30, 2026 the Company has 6,500 shares authorized, issued and outstanding of Series C convertible preferred stock classified as a current liability on the balance sheet due to its variable component upon conversion.

 

11. STOCKHOLDERS’ EQUITY (DEFICIT)

 

Preferred Stock

 

Series A Preferred Stock

 

In March 2015, the Company filed with the State of Nevada a Certificate of Designation establishing the designations, preferences, limitations and relative rights of 1,000,000 shares of the Company’s Series A preferred stock. Each share of Series A preferred stock has a par value of $0.001. Holders of the Series A preferred stock have the right to vote in aggregate, on all shareholder matters equal to 1,000 votes per share of Series A preferred stock not subject to adjustment for a stock split or reverse stock split. The shares of Series A preferred stock are not convertible into shares of common stock.

 

The Company has 1,000,000 shares of Series A preferred stock authorized, with 500,000 shares issued and outstanding as of September 30, 2026 and June 30, 2026, which were issued in March 2015 to members of the Company’s Board of Directors in consideration for services.

 

 
F-15

Table of Contents

 

 

Series B Preferred Stock

 

On December 21, 2015, the Company filed a Certificate of Designation for a new Series B convertible preferred stock with the State of Nevada following approval by the board of directors of the Company. The company authorized 1,500,000 shares of Series B convertible preferred stock with a par value of $0.001 per share and with a stated value of $0.001 per share (the “Stated Value”). Holders of Series B preferred stock shall be entitled to receive dividends, when and as declared by the Board of Directors out of funds legally available therefor. At any time and from time to time after the issuance of shares of the Series B preferred stock, each issued share of Series B preferred stock is convertible into 100 shares of the Company’s common stock (“Conversion Ratio”). The Conversion Ratio is subject to adjustment if the Company enters into a merger or spin off transaction but is not subject to adjustment for a stock split or reverse stock split. The holders of the Series B preferred stock shall have the right to vote together with holders of common stock, on an as “converted basis”, on any matter that the Company's shareholders may be entitled to vote on, either by written consent or by proxy. Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series B preferred stock shall be entitled to receive out of the assets of the Company, whether such assets are capital or surplus, for each share of Series B preferred stock an amount equal to the Stated Value, and all other amounts in respect thereof then due and payable prior to any distribution or payment shall be made to the holders of any junior securities.

 

The Company had 130,000 shares issued and outstanding as of September 30, 2026 and June 30, 2026.

 

Common Stock

 

As of September 30, 2026, we were authorized to issue up to 300,000,000 shares of common stock with a par value of $0.001.

 

The Company had 6,536,580 common shares issued and outstanding as of September 30, 2026 and June 30, 2026. As of September 30, 2026 and June 30, 2026, the Company has 125,000 shares of common stock that has been granted for services and compensation that has vested, but has not yet been issued. As a result, there is a common stock payable of $124,750 and $83,708 as of September 30, 2026 and June 30, 2026, respectively.

 

During the three months ended September 30, 2026, no common stock was issued by the company. During the three months ended September 30, 2026, common stock and additional paid-in capital were adjusted by $4 for rounding and additional common stock payable of $41,042 was recorded for shares vested, but not yet issued.

 

During the three months ended September 30, 2025, the Company issued 50,000 shares of its common stock and recognized $49,250 in stock-based compensation expense.

 

12. COMMITMENTS AND CONTINGENCIES

 

Legal Matters

 

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of the date of filing of this report, there were no pending or threatened lawsuits.

 

Short-Term Lease

 

In January 2026, the Company entered a 12-month short-term lease that provides for approximately 1,500 usable square feet, which the Company intends to use as office space. The monthly lease payments are $2,050 per month and the Company has a $6,000 security deposit, which is included in deposits assets on the balance sheet as of September 30, 2026. The lease agreement states that any extension or renewal of this lease shall require the execution of a new lease agreement with new terms and conditions and therefore the Company considers this a short-term lease.

 

13. DISCONTINUED OPERATIONS

 

Through June 6, 2024, we operated our digital asset mining operations in a hosted facility in Granbury, Texas. As of June 7, 2024, all miners were disconnected from their power source and many were sold during the year ended June 30, 2025. All remaining mining equipment was impaired and depreciated during the three months ended September 30, 2025. This marked a strategic shift in the Company’s operations.

 

 
F-16

Table of Contents

 

 

The following is a reconciliation of major classes of revenue and expenses classified as discontinued operations on our consolidated income statements:

 

 

 

During the Three Months Ended

September 30,

 

 

 

2026

 

 

2025

 

Major classes of line items constituting net income (loss) from discontinued operations

 

 

 

 

 

 

Depreciation and amortization

 

$-

 

 

$(17,151)

Impairment expense

 

 

-

 

 

 

(55,568)

Total major classes of line items constituting net income (loss) from discontinued operations

 

$-

 

 

 

(72,719)

 

Digital Asset Mining - Expenses

 

During the three months ended September 30, 2025, we impaired mining equipment and recognized impairment expense of $55,568. Additionally, during the three months ended September 30, 2025 we recognized depreciation on the mining equipment of $17,151. There was no income or expense from discontinued operations during the three months ended September 30, 2026.

 

14. SUBSEQUENT EVENTS

 

Management has evaluated subsequent events according to the requirements of ASC Topic 855, and has none to report.

 

 
F-17

Table of Contents

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

SPECIAL NOTE CONCERNING FORWARD-LOOKING STATEMENTS

 

We believe that it is important to communicate our future expectations to our security holders and to the public. This report, therefore, contains statements about future events and expectations which are “forward-looking statements” within the meaning of Sections 27A of the Securities Act of 1933 and 21E of the Securities Exchange Act of 1934, including the statements about our plans, objectives, expectations and prospects under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” You can expect to identify these statements by forward-looking words such as “may,” “might,” “could,” “would,” “will,” “anticipate,” “believe,” “plan,” “estimate,” “project,” “expect,” “intend,” “seek” and other similar expressions. Any statement contained in this report that is not a statement of historical fact may be deemed to be a forward-looking statement. Although we believe that the plans, objectives, expectations and prospects reflected in or suggested by our forward-looking statements are reasonable, those statements involve risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements, and we can give no assurance that our plans, objectives, expectations and prospects will be achieved.

 

Important factors that might cause our actual results to differ materially from the results contemplated by the forward-looking statements are contained in the “Risk Factors” section of and elsewhere in our Annual Report on Form 10-K for the year ended June 30, 2026 filed on October 13, 2026 and in our subsequent filings with the Securities and Exchange Commission. The following discussion of our results of operations should be read together with our financial statements and related notes included elsewhere in this report.

 

GENERAL

 

We were incorporated in the State of Nevada on March 22, 2011 under the name Lightcollar, Inc. In March 2015, we changed our name to EMS Find, Inc. On May 30, 2017, Integrated Ventures, Inc. (“Integrated Ventures”), a Nevada corporation, was formed as a wholly owned subsidiary of the Company. Pursuant to an Agreement and Plan of Merger dated May 30, 2017, Integrated Ventures was merged into the Company, with the Company being the surviving corporation and changing its name to Integrated Ventures, Inc. In July 2024, the Company formed three wholly-owned subsidiaries, MedWell Direct, LLC (“MedWell Direct”), MedWell Facilities, LLC (“MedWell Facilities”), and MedWell USA, LLC (“MedWell USA), all of which were organized in the State of Nevada. In June 2025, we changed our name to MedWellAI, Inc.

 

On August 29, 2024, the Company, through MedWell Direct, consummated its acquisition of 51% of the membership interests of Healthy Lifestyle USA LLC, a Florida limited liability company (“Healthy Lifestyle”).

 

We are a publicly traded company (OTCQB: MWAI), based in Clearwater, Florida, that is focused on earning commissions through the use of a fully automated e-commerce platform that connects in-office buyers with multiple FDA-registered 503B pharmacies, offering GLP-1 weight management therapies, peptides and other compounds.

 

The Company also markets a turnkey, custom solution for qualified procurement agents and resellers to market in-office use products.

 

This e-commerce platform enables procurement agents and resellers to market products to licensed healthcare providers, wellness spas and telemedicine companies in a 100% automated, cost-effective, efficient, compliant and profitable manner without requiring any infrastructure investment.

 

Key features of the platform include access to multiple 503B outsourcing facilities, over 100 products, personalized pricing, direct payment deposits, custom domain options, and onboarding support.

 

 
3

Table of Contents

 

The platform allows for seamless ordering, fulfillment, and shipping managed directly by the 503B facilities.

 

Financial

 

Revenues from commissions were $76,390 and $94,887 for the three months ended September 30, 2026 and 2025, respectively.

 

Rental income was $0 and $22,500 for the three months ended September 30, 2026 and 2025, respectively. Cost of revenues for rental income was $0 and $7,550 for the three months ended September 30, 2026 and 2025, respectively.

 

Historically, we have funded our operations primarily from cash generated from our commissions revenue, convertible notes payable and preferred stock. During the three months ended September 30, 2026 and 2025, we generated negative cash flow from operations. During the three months ended September 30, 2026 we received proceeds of $195,000 from a convertible note.

 

Recent Material Developments

 

On July 21, 2026, the Company entered into a convertible note payable for $225,000. The note matures on July 21, 2027 and bears a flat interest charge of $27,000 that shall not be reduced or pro-rated in the event of prepayment. In addition, upon an event of default the interest rate will be equal to the lesser of 24% or the maximum rate of interest under the law. The convertible note requires a payment of $126,000 on December 29, 2026 with payments of $21,000 each month thereafter until the maturity of the note. At anytime after an event of default, the holder may convert the note into common shares at a rate per share equal to 80% of the lowest trading price in the 10 trading days prior to conversion. The Company received net proceeds of $195,000 after recording a $25,000 original issue discount and $5,000 in debt discount for legal fees. The total debt discount of $30,000 will be amortized over the life of the loan.

 

RESULTS OF OPERATIONS

 

THREE MONTHS ENDED SEPTEMBER 30, 2026 COMPARED TO THE THREE MONTHS ENDED SEPTEMBER 30, 2025

 

Revenues

 

Our commission revenues decreased to $76,390 during the three months ended September 30, 2026 from $94,887 during the three months ended September 30, 2025.

 

Our rental revenues decreased to $0 during the three months ended September 30, 2026 from $22,500 during the three months ended September 30, 2025. On June 1, 2026, our only lease customer notified the Company the lease would not be renewed.

 

Expenses

 

General and administrative expenses decreased to $316,195 in the three months ended September 30, 2026 from $428,771 in three months ended September 30, 2025. The decrease resulted primarily from non-cash stock-based compensation expense of $49,250 that occurred in the prior year and not the current year, a decrease in marketing expense and a decrease in wages due to two less employees compared to the prior year period.

 

Depreciation and amortization decreased to $6,125 in the three months ended September 30, 2026 from $8,307 in the three months ended September 30, 2025. The decrease is due to leasehold assets no longer being depreciated as they were fully amortized and disposed after the three months ended September 30, 2025.

 

 
4

Table of Contents

 

Other Income (Expense)

 

Our other income (expense) was comprised of the following for the three months ended September 30:

 

 

 

Three Months Ended

September 30,

 

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

Other income

 

 

-

 

 

 

1,207

 

Interest expense

 

$(45,939 )

 

$(12,936 )

Loss on exchange of Series C & D preferred shares

 

 

-

 

 

 

(241,918 )

 

 

$(45,939 )

 

$(253,647 )

 

Other income decreased to $0 in the three months ended September 30, 2026 from $1,207 during the three months ended September 30, 2025.

 

Interest expense increased to $45,939 in the three months ended September 30, 2026 from $12,936 during the three months ended September 30, 2025. The increase was due to a one-time, up front interest charge on a new $225,000 convertible note, amortization of the convertible note debt discount and interest on an outstanding note.

 

During the three months ended September 30, 2025 we exchanged 1,125 Series C and 3,000 Series D preferred shares for 6,500 Series C convertible preferred shares. As a result, during the three months ended September 30, 2025 we recognized a $241,918 loss on exchange of Series C and D preferred shares.

 

Discontinued Operations

 

During the three months ended September 30, 2025, we recognized net losses from discontinued operations of $72,719, as the Company strategically moved from the digital asset mining industry to health and wellness industry.

 

Net Loss Attributable to shareholders

 

During the three months ended September 30, 2026 and 2025, we reported a net loss attributable to shareholders of $287,173 and $651,878, respectively.

 

LIQUIDITY AND CAPITAL RESOURCES

 

Overview

 

As of September 30, 2026, we had total current assets of $198,069, including cash of $180,040 and total current liabilities of $8,331,076. We had total stockholders’ deficit attributable to shareholders of $8,266,584 as of September 30, 2026 compared to $7,979,411 as of June 30, 2026.

 

Sources and Uses of Cash

 

During the three months ended September 30, 2026, we used cash in operations of $101,182 as a result of our net loss from continuing operations of $291,869, other non-cash expenses of $11,961, decrease in receivables of $6,070, decrease in prepaids of $1,556, increase in accounts payable of $5,189, increase in accrued expenses of $34,985, and an increase of $130,926 to due to related party.

 

During the three months ended September 30, 2025, we used cash in operations of $170,781 as a result of our net loss from continuing operations of $580,888, loss on exchange of Series C & D preferred shares of $241,918, lease costs exceeding leases payments of $7,550, other non-cash expenses of $57,557, decrease in receivables of $287, and increases in accrued expenses of $13,309, and due to related party of $118,588 offset by increases in prepaid expenses of $1,244, accounts payable of $27,655, and deferred revenue of $203.

 

During the three months ended September 30, 2026, there were no cash flows from investing activities. During the three months ended September 30, 2025, we used net cash in investing activities – continuing operations of $7,308, comprised of cash used for leasehold improvements.

 

During the three months ended September 30, 2026 we had cash flows from financing activities of $195,000 from a convertible note payable. During the three months ended September 30, 2025, we had no cash flows from financing activities.

 

 
5

Table of Contents

 

Going Concern

 

Historically, the Company has reported recurring net losses from operations and used net cash in operating activities. As of September 30, 2026, the Company’s current liabilities exceeded its current assets by $8,133,007 and the Company had an accumulated deficit of $90,550,518. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

 

The accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The ability of the Company to reach a successful level of operations is dependent on the execution of management’s plans, which include the raising of capital through the debt and/or equity markets, until such time that funds provided by operations are sufficient to fund working capital requirements. If the Company were not to continue as a going concern, it would likely not be able to realize its assets at values comparable to the carrying value or the fair value estimates reflected in the balances set out in the preparation of the consolidated financial statements.

 

There can be no assurances that the Company will be successful in attaining a profitable level of operations or in generating additional cash from the equity/debt markets or other sources to fund its operations. The consolidated financial statements do not include any adjustments relating to the recoverability of assets and classification of assets and liabilities that might be necessary. Should the Company not be successful in its business plan or in obtaining the necessary financing to fund its operations, the Company would need to curtail certain or all operational activities and/or contemplate the sale of its assets, if necessary.

 

SIGNIFICANT ACCOUNTING POLICIES

 

Our significant accounting policies are disclosed in Note 2 to the accompanying financial statements. The following is a summary of those accounting policies that involve significant estimates and judgment of management.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.

 

Receivables

 

Receivables are carried at net realizable value, representing the outstanding balance less an allowance for doubtful accounts based on a review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual receivables and receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded when received.

 

Property and Equipment

 

Property and equipment, consisting primarily of computer, other equipment, and leasehold improvements is stated at the lower of cost or estimated realizable value and is depreciated when placed into service using the straight-line method over estimated useful lives. Management has assessed the basis of depreciation of these assets and believes they should be depreciated over three – five years depending on the asset. Computers, due to their technological obsolescence reflecting rapid development of hardware that have faster processing capacity and other factors are depreciated over three years. Leasehold improvements are depreciated over five years representing the lease term. Maintenance and repairs are expensed as incurred and improvements are capitalized. Gains or losses on the disposition of property and equipment are recorded upon disposal.

 

Payments to equipment suppliers prior to shipment of the equipment are recorded as equipment deposits.

 

 
6

Table of Contents

 

Intangible Assets

 

The Company accounts for its intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Subtopic 350-30, General Intangibles Other Than Goodwill. ASC Subtopic 350-30, which requires assets to be measured based on the fair value of the consideration given or the fair value of the assets (or net assets) acquired, whichever is more clearly evident and, thus, more reliably measurable. Under ASC Subtopic 350-30 any intangible asset with a useful life is required to be amortized over that life and the useful life is to be evaluated every reporting period to determine whether events or circumstances warrant a revision to the remaining period of amortization. If the estimate of useful life is changed the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. Costs to renew or extend the term of intangible assets are recognized as an expense when incurred.

 

Impairment of Long-Lived Assets

 

All assets, including intangible assets subject to amortization, are reviewed for impairment when changes in circumstances indicate that the carrying amount of the asset may not be recoverable in accordance with ASC 350 and ASC 360. If the carrying amount of the asset exceeds the expected undiscounted cash flows of the asset, an impairment charge is recognized equal to the amount by which the carrying amount exceeds fair value or net realizable value. The testing of these intangibles under established guidelines for impairment requires significant use of judgment and assumptions. Changes in forecasted operations and other assumptions could materially affect the estimated fair values. Changes in business conditions could potentially require adjustments to these asset valuations.

 

Discontinued Operations

 

The Company follows the provisions of ASC 205-20, Presentation of Discontinued Operations, which requires separate reporting if a company sells part of its business. In order to recognize discontinued operation a major product line or division of an entity must be both a component and a strategic shift in operations.

 

Convertible Preferred Stock

 

The Company follows the provisions of ASC 480, Distinguishing Liabilities from Equity in determining if a financial instrument should be classified as a liability or equity on the balance sheet. This standard provides, among others, that the conversion of preferred stock into a variable number of equity shares and at inception, the monetary value is fixed, the instrument should be classified as a liability. As such upon the exchange of the Series C & D preferred shares on August 1, 2025 into convertible preferred stock, the Company determined the Series C convertible preferred stock met the requirements to be classified as a liability. Further, due to their convertible nature at any time at the option of the holder they are presented as current liability on the balance sheet.

 

Stock-Based Compensation

 

The Company accounts for all equity-based payments in accordance with ASC Topic 718, Compensation – Stock Compensation. ASC Topic 718 requires companies to recognize in the statement of operations the grant-date fair value of stock awards, stock options, warrants and other equity-based compensation issued. The value of the portion of an award that is ultimately expected to vest is recognized as an expense over the requisite service periods using the straight-line attribution method. The fair value of a stock award is recorded at the fair market value of a share of the Company’s stock on the grant date. The Company estimates the fair value of stock options and warrants at the grant date by using an appropriate fair value model such as the Black-Scholes option pricing model or multinomial lattice models.

 

The Company accounts for non-employee share-based awards based upon ASC 505-50, Equity-Based Payments to Non-Employees. ASC 505-50 requires the costs of goods and services received in exchange for an award of equity instruments to be recognized using the fair value of the goods and services or the fair value of the equity award, whichever is more reliably measurable. The fair value of the equity award is determined on the measurement date, which is the earlier of the date that a performance commitment is reached or the date that performance is complete. Generally, our awards do not entail performance commitments. When an award vests over time such that performance occurs over multiple reporting periods, we estimate the fair value of the award as of the end of each reporting period and recognize an appropriate portion of the cost based on the fair value on that date. When the award vests, we adjust the cost previously recognized so that the cost ultimately recognized is equivalent to the fair value on the date the performance is complete.

 

 
7

Table of Contents

 

Revenue Recognition

 

We recognize revenue in accordance with ASC 606, Revenue from Contracts with Customers. This standard provides a single comprehensive model to be used in the accounting for revenue arising from contracts with customers, including industry-specific guidance. The standard’s stated core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASC 606 includes provisions within a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.

 

The following table presents the Company’s revenue by revenue source:

 

 

 

Three Months Ended

September 30,

 

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

Commissions

 

$76,390

 

 

$94,887

 

Rental income

 

 

-

 

 

 

22,500

 

 

 

$76,390

 

 

$111,877

 

 

Commissions

 

The Company earns commissions by informing, educating, and initiating sales of health and wellness products offered by a third party to customers. The commissions earned are based on the gross sales of products to customers less costs and fees. Periodically, the third party computes the commission payable since the previous Reconciliation Date. The third party then pays the Company the amount due. The transactions price is set as the commissions to be received based on the agreed terms. The commissions are earned at a point in time upon the successful sale of products to a customer.

 

The timing of commission revenue recognition may differ from the timing of payment by the Company’s customers. The Company records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. As of September 30, 2026, the Company had receivables from commissions of $3,029.

 

 
8

Table of Contents

 

Rental Income

 

The Company recognizes rent revenue from the lease of its sub-leased properties in accordance with ASC 842, Leases. The sub-lease is categorized as an operating lease according to ASC criteria for the lease definitions. Rent revenue is recognized on a straight-line basis over the lease term, reflecting the pattern of the economic benefits derived from the lease.

 

The Company’s leases generally have fixed rental payments over the lease term, with occasional escalations based on predetermined factors. Rent revenue is recognized monthly as the lessor fulfills its obligations under the lease agreement.

 

Any lease incentives or concessions provided to lessees, such as rent-free periods or tenant improvement allowances, are recognized as a reduction of rent revenue over the lease term.

 

During the year ended June 30, 2026, the Company had only one lease arrangement with a single customer. On June 1, 2026 the customer notified the Company the lease would not be renewed.

 

Fair Value of Financial Instruments

 

Assets and liabilities measured at fair value on a recurring basis

 

We recognize financial instruments under the following fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows:

 

 

Level 1:

quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

 

 

 

Level 2:

observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

 

 

 

Level 3:

assets and liabilities whose significant value drivers are unobservable.

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

 

 
9

Table of Contents

 

The Company will update its assumptions each reporting period based on new developments and record such amounts at fair value based on the revised assumptions until the agreements expire or contingency is resolved, as applicable.

 

As of September 30, 2026 and June 30, 2026 the Company did not have any assets and liabilities measured at fair value on a recurring basis.

 

OFF BALANCE SHEET ARRANGEMENTS

 

As of September 30, 2026, we have no off-balance sheet arrangements.

 

RECENTLY ISSUED ACCOUNTING POLICIES

 

There were no new accounting pronouncements issued or proposed by the FASB during the three months ended September 30, 2026 and through the date of filing this report which the Company believes will have a material impact on its financial statements.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a smaller reporting company, as defined by Item 10 of Regulation S-K, the Company is not required to provide the information required by this item.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)). Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered in this report, our disclosure controls and procedures were not effective to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

 

Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. To address the material weaknesses, we performed additional analysis and other post-closing procedures in an effort to ensure our financial statements included in this quarterly report have been prepared in accordance with generally accepted accounting principles. Accordingly, management believes that the financial statements included in this report fairly present in all material respects our financial condition, results of operations and cash flows for the periods presented.

 

Management’s Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Securities Exchange Act, as amended. Our management assessed the effectiveness of our internal control over financial reporting as of September 30, 2026. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. We have identified the following material weaknesses:

 

 
10

Table of Contents

 

1.

As of September 30, 2026, we did not maintain effective controls over the control environment. Specifically, the Board of Directors does not currently have any independent members and no director qualifies as an audit committee financial expert as defined in Item 407(d)(5)(ii) of Regulation S-K. Since these entity level programs have a pervasive effect across the organization, management has determined that these circumstances constitute a material weakness.

2.

As of September 30, 2026, due to the inherent issue of segregation of duties in a small company, we have relied heavily on entity or management review controls and engaged an outside financial consultant to lessen the issue of segregation of duties over accounting, financial close procedures and controls over financial statement disclosure. Accordingly, management has determined that this control deficiency constitutes a material weakness.

 

 

 

 

3.

As of September 30, 2026, we did not establish a written policy for the approval, identification and authorization of related party transactions. Accordingly, management has determined that this control deficiency constitutes a material weakness.

 

Because of these material weaknesses, management has concluded that the Company did not maintain effective internal control over financial reporting as of September 30, 2026, based on the criteria established in “Internal Control-Integrated Framework” issued by the COSO.

 

Changes in Internal Control Over Financial Reporting

 

There have been no changes in the Company’s internal control over financial reporting through the date of this report or during the quarter ended September 30, 2026, that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

 
11

Table of Contents

 

PART II

 

ITEM 1. LEGAL PROCEEDINGS

 

We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company, threatened against or affecting our company, our common stock, or our company’s directors, officers or affiliates, or in which any owner of record or beneficial owner of more than 5% of any class of our voting securities is a party adverse to us or has a material interest adverse to us.

 

ITEM 1A. RISK FACTORS

 

There have been no material changes to the risk factors set forth in our Annual Report on Form 10-K for the fiscal year ended June 30, 2026.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES

 

During the three months ended September 30, 2026, no shares of common stock were issued.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

As of September 30, 2026, the Company was in default on a $500,000 promissory note that matured on January 15, 2023. As of the date of this report, the total arrearage was $611,799, consisting of $500,000 in principal and $111,799 in interest.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

During the three months ended September 30, 2026, no director or officer of the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

There is no other information required to be disclosed under this item which was not previously disclosed.

 

 
12

Table of Contents

 

ITEM 6. EXHIBITS

 

EXHIBIT INDEX

 

Exhibit Number

 

Exhibit Description

31.1*

 

Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer and Principal Financial Officer

 

 

 

32.1**

 

Section 1350 Certification of Principal Executive Officer and Principal Financial Officer

 

 

 

101.INS*

 

Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).

 

 

 

101.SCH*

 

Inline XBRL Taxonomy Extension Schema

 

 

 

101.CAL*

 

Inline XBRL Taxonomy Extension Calculation Linkbase

 

 

 

101.DEF*

 

Inline XBRL Taxonomy Extension Definition Linkbase

 

 

 

101.LAB*

 

Inline XBRL Taxonomy Extension Label Linkbase

 

 

 

101.PRE*

 

Inline XBRL Taxonomy Extension Presentation Linkbase

 

 

 

104*

 

Cover Page Interactive Data File (formatted inline XBRL and contained in Exhibit 101)

_________

* Filed herewith.

** Furnished herewith. This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference, in accordance with Item 601(b)(32)(ii) of Regulation S-K.

 

 
13

Table of Contents

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the Company has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

MEDWELLAI, INC.

Dated: November 16, 2026

By:

/s/ Steve Rubakh

Chief Executive Officer, Chief Financial Officer, and Director

(Principal Executive Officer and Principal Financial and Accounting Officer)

 

 
14

 

Keep reading